Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Holding BLUE?
Track your performance easily
BLUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.29 - $5.53
Previous Close$0.3
Volume1.65M
Average Volume (3M)6.41M
Market Cap
$57.93M
Enterprise Value$353.70M
Total Cash (Recent Filing)$70.65M
Total Debt (Recent Filing)$365.02M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Feb 25, 2025EPS Estimate
-$0.3Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding194,444,345
10 Day Avg. Volume6,672,066
30 Day Avg. Volume6,413,497
Standard Deviation0.22
R-Squared0.04
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-10.10
Price to Sales (P/S)1.12
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.66
Enterprise Value/Gross Profit-87.77
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$2.30Price Target Upside677.29% Upside
Rating ConsensusHold
Number of Analyst Covering7
Bluebird Bio News
PremiumCompany Announcements
Bluebird bio Reports Q3 2024 Earnings and Future OutlookBulls Say, Bears Say
Bulls Say
Financial PerformanceCost reduction efforts should reduce operating expenses by 20% and allow for break-even to be achieved.
Market ExpansionBLUE has activated more than 70 QTCs for Zynteglo and Lyfgenia, indicating a broader treatment reach.
Product DemandA recent ramp in sales, driven by Lyfgenia uptake, leaves room for substantial future growth.
Bears Say
Cash Flow And FundingThe cash runway is currently a concern, with sufficient funds expected only until the first quarter of next year, which may weigh on the shares until a financial path forward is announced.
Financial PerformanceThird-quarter revenues were slightly below expectations, although not particularly concerning due to the high influence of timing on individual patient dosing.
Product Safety ConcernsSeven of the 67 patients enrolled in the various studies on Skysona developed hematologic cancers.
---
Ownership Overview
0.82% Insiders
14.00% Mutual Funds
3.41% Other Institutional Investors
71.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $0.29 and its highest was $5.53 in the past 12 months.
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Feb 25, 2025 which is in 96 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on Nov 14, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.364 by $0.054.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.3.
How many shares outstanding does bluebird bio have?
bluebird bio has 194,444,350 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.364. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Graham Capital Management, L.P.. It holds bluebird bio’s shares valued at N/A.
---
Bluebird Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.30 (677.29% Upside)
$2.30 (677.29% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.08%
12-Months-Change
Fundamentals
Return on Equity
-270.20%
Trailing 12-Months
Asset Growth
-24.21%
Trailing 12-Months
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q3 2024
0:00 / 0:00
---
BLUE Stock 12 Month Forecast
Average Price Target
$2.30
▲(677.29% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+15.33%
reiterated a sell rating 7 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +15.33% per trade.
---